



NOVEMBER 2021




Does early treatment with highly effective DMT improve prognosis for people with MS?

WELCOME TO THE NOVEMBER NEWSLETTER

November is the month of thanksgiving and we'd like to give thanks this month for your continued commitment to the DELIVER-MS study. In particular, a record number of sites achieved the monthly target of enrolling 1-2 participants this month. However, some sites have been inactive for some time (see below). Please remember that for now, **you can continue recruit to the OBSERVATIONAL study even if you are struggling to randomise.**

This month we share a feature on the DELIVER-MS study that was produced by the UK MS Society - check out an extract below.

MONTHLY ENROLLMENT AS OF 14TH NOV



SITES FULLY ENROLLED:

UCL

EXTRACT FROM:



Gwen Covey-Crump, Patient-Advisor "When you're diagnosed with MS, you don't know how quickly you're going to progress. For me, the offer of a very safe, but potentially less effective drug, or a less safe but highly effective drug is an impossible decision. So in 2012 when I helped the MS Society decide their top 10 research priorities, I wanted to make sure this was addressed; DELIVER-MS is an outcome of that. I've enjoyed helping to shape the trial from the start. I think it has a novel approach and offers a patient-friendly choice."



Daniel Ontaneda, Trial co-lead

"Finding solutions for MS problems pushes me to be excited about research and try to find answers. Since the development of highly effective DMTs over 15 years ago, we've developed safer ways of using them and newer safer, medications. So, the question is, should we just be using these from the start? We want DELIVER-MS to provide clarity and consistency to help pwMS and neurologists."

Lucy, Trial participant

"I didn't take anyone to my diagnosis as I genuinely thought there was nothing wrong with me! So it kind of hit me out of the blue. When my neurologist told me about the DELIVER-MS study, it seemed like a sensible idea. The overall contact and care is regular and reassuring. Why wouldn't you sign up for that? These kind of trials will hopefully help people like me to continue to live a normal life."




For the full feature click on the link at the end of the newsletter.

NEWS AND UPDATES

- 🧠 Please ensure you enter all eCRF data within 10 days.
- 🧠 It is vital that MRIs (especially **Month 36**) are performed within window. Please speak to us if you are facing difficulties with this. (*Nikos has said he plans to tattoo the M36 MRI dates of his participants on his bicep...*).
- 🧠 DMT Summary Forms must be completed for DMT start (at either Baseline or Month 3) as well as for any subsequent switches of DMT.
- 🧠 BIOBANKING:
 - 🧠 All sites: please do not send biobank samples on Fridays as they cannot be processed.
 - 🧠 All sites: Please remember to keep your serum storage logs up to date and send to Harriet (UK) or Praneeta (US) monthly
 - 🧠 US sites: please send Praneeta/Sarah copies of any FedEx invoices you receive - we apologize for any inconvenience and are continuing to work with Cardinal Health to resolve this.

FINAL THOUGHTS: RECRUIT, RECRUIT, RECRUIT!!

Thank you for everything you do to help answer the important question of escalation or highly effective therapy, which has become even more poignant during the COVID-19 pandemic. We are at a key stage in enrollment and need your ongoing commitment to complete the study. Remember this is your study and we would love to hear ideas for research with the data and analysis, including biomarkers!



Relevant Links

Full MS Society article on DELIVER-MS: www.mssociety.org.uk/research/latest-research/research-blog/behindthetrial-comparing-treatment-approaches-people-newly-diagnosed-ms

DELIVER-MS website:

www.deliver-ms.com

TREAT-MS website:

<https://treat-mstrial.org/>

DELIVER-MS mailing address:

planchs@ccf.org (US) and harriet.howard2@nuh.nhs.uk (UK)